High-dose chemotherapy and/or radiation followed by transplantation of allogeneic bone marrow (BM) or blood
HPC from an HLA-matched donor is potentially curative treatment for patients with hematologic malignancies with poor prognoses. [1] [2] [3] [4] [5] [6] [7] Unfortunately, the applicability of allogeneic transplantation is limited by the availability of a suitable matched donor. Fewer than one-third of patients who might benefit from an allogeneic transplant have an HLAidentical sibling and fewer than 5% of patients have a nonsibling relative who is HLA phenotypically identical or is mismatched at only one HLA-locus. 8, 9 Despite the existence of a worldwide registry that includes more than four million HLA-typed volunteers, about 40% of patients do not have an HLA-compatible donor. In addition, the median time elapsed from the initiation of an unrelated donor search to the transplant procedure is 120 days. 10 In contrast, partially mismatched, related donors who share one HLA haplotype with the patient and are mismatched at two to three other HLA loci on the non-shared haplotype, are readily available for almost all patients. 11 The use of partially mismatched donors has been limited because of the treatment-related mortality associated with this type of transplant. 12 During the 1980s, transplantation of BM HPC from family donors who were not fully histocompatible with the recipients was unsuccessful because of graft failure (24%) and severe acute GVHD (60-70%). 12 Although depletion of T cells from the donor's bone marrow succeeded in preventing GVHD in children with severe combined immunodeficiency disease, 13 the results of this procedure were disappointing in patients with leukemia. In leukemia patients, the benefit of preventing GVHD was offset by increased risks of graft failure and disease relapse. [14] [15] [16] [17] Resistance to engraftment appears to be mediated by hostderived cytotoxic T lymphocyte precursors that survive myeloablative conditioning. Animal studies have demonstrated that host resistance to the engraftment of T celldepleted haploidentical BM can be overcome by administering large doses of stem cells. 18 The group from Perugia reported full donor-type engraftment following large doses of T cell-depleted hematopoietic stem cells from HLA haplo-identical relatives in patients with high-risk acute leukemia. No severe acute GVHD was observed despite the fact that these patients did not receive post-transplant immunosuppressive therapy. 19 In the present study the results of blood HPC transplantation from HLA-mismatched relatives using a modified Perugia approach are analyzed and reported.
Materials and methods

Patients
Between September 1999 and June 2001, 19 patients with poor-risk hematologic malignancy received HPC transplants from PMRDs ( Table 1 ). The study patients were selected because they lacked a suitable HLA-matched volunteer unrelated donor (VUD) or the presence of advanced or refractory malignancy made waiting for a matched VUD impractical. The treatment protocol was reviewed and approved by the Institutional Review Board and all patients gave informed consent. An IDE was granted by the FDA for the use of the Isolex 300i in this setting.
Donors
Family members were assessed for HLA compatibility using standard serologic testing for HLA class I and molecular testing for HLA class II antigens. Donor selection was based on the presence of a shared HLA haplotype, disparity of a HLA class I loci that predicts NK cell reactivity, 20 age, general health, weight, gender, and viral serology. In eight cases the donor was a parent, in five cases a sibling, in five cases a child of the recipient and in one case a cousin (Table 2) .
Mobilization and collection
Donors received G-CSF (Amgen, Thousand Oaks, CA, USA) 10 g/kg subcutaneously once daily based on actual body weight. Prior to patient enrollment on the study donors were assessed to determine whether they could tolerate apheresis via peripheral veins. If venous access via peripheral veins was deemed to be inadequate, then a central line was placed.
Daily leukapheresis began on the 5th day of G-CSF administration and the target number of CD34 + cells in the graft (post processing) was 5 ϫ 10 6 CD34 + cells/kg. The endpoint of each leukapheresis collection was either the processing of a maximum of 20 l of whole blood or a maximum of 4 h of leukapheresis.
Stem cell processing and transplantation
The first leukapheresis product was stored at 4°C overnight and pooled with the second apheresis product collected on the following day. The combined apheresis products were processed by CD34
+ cell selection and T cell and B cell depletion using the One-Step Positive/Negative Selection System (Isolex 300i; Baxter Healthcare, Deerfield, IL, USA). The CD34 + enriched product was infused, without cryopreservation, directly to the patient after processing on day 0. In 10 patients a combination of anti-CD4, CD8, CD19 and CD20 monoclonal antibodies (Baxter) were used for T cell and B cell depletion; in nine patients a combination of anti-CD2, CD19 and CD20 (Nexell Therapeutics) were used. A third and a fourth leukapheresis was performed (if needed) and processed and was infused on day +1 and day +2 until the target CD34 + cell dose was reached. Cell content of the leukapheresis products was analyzed by flow cytometry using a modified ISHAGE protocol for CD34 + cells (CD34-phycoerythrin, CD45-fluorescein, CD38-allophycocyanin and propidium iodide) and a panel of monoclonal antibodies for T cells, B cells, NK cells and dendritic cells. 21 
Conditioning regimen
The conditioning regimen (FITFA) consisted of fractionated TBI (1200 cGy in 200 cGy fractions twice daily for 3 consecutive days), thiotepa (5 mg/kg every 12 h for two doses), fludarabine (40 mg/m 2 daily for 5 consecutive days), and anti-thymocyte antisera (ATGAM, PharmaciaUpjohn, Kalamazoo, MI, USA) 20 mg/kg daily for 3 con-secutive days in three patients, Thymoglobulin (Sangstat, Fremont, CA, USA) 2.5 mg/kg daily for 4 consecutive days in two patients, or Thymoglobulin (1.5 mg/kg daily for 4 consecutive days in 12 patients). No post-transplant immunosuppressive treatment was given for GVHD prophylaxis.
Assessment of engraftment and immunologic studies
The day of neutrophil engraftment was considered to have occurred on the first day the ANC was at least 500/mm 3 for 3 consecutive days. Platelet engraftment was the first day the platelet count was greater than 20 000/mm 3 without platelet transfusion for the previous 7 days. Cytogenetic, heteromorphism or VNTR analyses were routinely performed to monitor donor origin of blood and marrow cells. Subsets of peripheral blood lymphoid cells present after transplant were identified by four-color immunofluorescence and flow cytometry. The diagnosis and degree of acute and chronic GVHD were assessed according to consensus criteria.
22,23
Supportive care
Patients were treated in a positive pressure high efficiency particulate air (HEPA)-filtered room. Prophylactic antimicrobal therapy (Penicillin 500 mg p.o. twice a day and Cipro 500 mg p.o. twice a day) was administered until neutrophil engraftment. Intravenous Ablcet (2.5 mg/kg) was given daily until neutrophil engraftment, then continued three times weekly until 100 days post transplant for antifungal prophylaxis. The first three patients received 10 g/kg/day G-CSF (Amgen) from 1 day post transplant until neutrophil engraftment occurred. The subsequent 15 patients received no post-transplant growth factor. Patients did not receive CMV prophylaxis with ganciclovir. All patients were monitored for CMV and EBV infection by PCR on weekly blood samples. Pre-emptive therapy with ganciclovir was initiated for patients with detectable CMV DNA in the serum as assayed by quantitative PCR. All patients received pneumocystis prophylaxis (Bactrim DS 1 p.o. on M/W/F or dapsone 200 mg p.o. starting at day 35 post transplant).
Statistical analyses
The time between initial consult and transplantation was compared between the group of 54 patients with high-risk hematological malignancies (excluding CML in chronic phase and low grade non-Hodgkin's lymphoma) referred for VUD transplants between 1998 and 2000 and 20 patients with high-risk hematologic malignancies referred for PMRD transplants during the period of 1999-2001. The statistical endpoints for this comparison were the fraction of patients transplanted and the time between initial consultationation and transplantation. Analysis of the time period between the initial consultation and the time of actual transplantation was calculated using the Kaplan-Meier probability method. 24 The log-rank test was used to compare difference in the curves to evaluate the differences between the two groups.
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Results
Graft characteristics and hematopoietic engraftment
CD34
+ enriched blood HPC allografts contained a mean of (Ϯs. 
Cellular immune reconstitution post transplant
The number of blood T cells, B cells and NK cells following transplantation was analyzed routinely at days 28, 60, 75, 100, 125, 180 and 365 post transplant in all evaluable patients. NK cells were the predominate blood lymphocyte during the first 2 months post transplant and were present at median level of Ͼ150/mm 3 throughout the follow-up period. In contrast, the median number of CD3-positive cells in the blood was less than 20 cells/mm 3 at day 100 post transplant and less than 100 cells/mm 3 at 6 months post transplant.
Graft-versus-host disease
Among the 15 patients who received Thymoglobulin as part of their conditioning regimen, two patients developed grade biopsy proven I/II skin acute GVHD that resolved with topical steroid therapy. Among the three patients who received ATGAM as part of their conditioning regimen, two patients developed acute GVHD (one grade II and one grade III) which required systemic steroids.
Survival
Six of 19 patients are surviving at a median follow-up of 10 months (range 3-22) (Table 3) . Relapse was the most frequent cause of death. Seven patients relapsed at a median time of 103 days following transplant (range 74-228) and six of seven patients died. Three deaths were due to systemic bacterial infections (with streptococcus in two cases and pseudomonas in one case), two to invasive aspergillus. One case of EBV-related post-transplant lymphoproliferative disease has occurred and is now in remission following 4 weekly infusions of Ritaximab. One patient died of interstitial pneumonia. As shown in Figure 1 , overall 2 year survival for this group of high-risk patients is estimated to be 25%. Table 3 Causes of death 
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Discussion
The aim of our pilot study was to test a 'modified Perugia' approach that would provide fast, and stable engraftment with low incidence of GVHD.
To further reduce the risk of regimen-related toxicity, and make the delivery of TBI easier we substituted hyperfractionated TBI for single-fraction TBI, without changing the dose or schedule of thiotepa, or fludarabine as described by Aversa et al. 25 Hyperfractionation of TBI decreases its immunosuppressive effect and toxicity to normal tissues, while retaining the same myeloablative effect as singlefraction TBI. 26, 27 We also varied the total dose of ATG during this study. The first three patients received 60 mg/kg equine ATG; the next two patients received rabbit ATG at a dose of 10 mg/kg and the remaining patients received rabbit ATG at a dose of 6 mg/kg. Lower doses of ATG were used in an attempt to limit the long-term immunosuppression post transplant. The FITFA conditioning regimen using hyperfractionated TBI and lower dose ATG was well tolerated and it was sufficiently immunosuppressive to allow rapid engraftment.
Neutrophil engraftment among recipients of CD34 + cell enriched blood HPC from PMRDs was rapid, stable, and predictable. Of note, doses of CD34 + donor cells used to transplant these adult patients (median weight 86 kg) were somewhat larger than those that have been used in HLA matched allogeneic blood HPC transplants. 28 However, the cell doses used in the present study do not constitute 'mega' dose (Ͼ10 ϫ 10 6 /kg) of CD34 + cells/kg as described by Reisner and Martelli. 29 One important question concerning alternative donor allogeneic transplantation is the availability of suitable donor grafts and the time needed to procure them. We compared the time between the initial transplant consultation and the actual transplant for 20 patients referred to our center for consideration of haplo-identical transplantation and a group of 54 patients referred to our center for allogeneic transplantation using a volunteer unrelated donor. Only 33% of 54 patients who were potential VUD transplant candidates successfully underwent transplantation at a median of 3.6 months (range 2-8) following initiation of VUD search. Sixty-seven percent had no available optimal donor or their disease progressed too quickly to allow successful procurement of an allogeneic graft from a HLA matched volunteer donor. No patients in this group received transplant at other centers. Conversely, 19/20 patients referred for PMRD allogeneic transplants successfully underwent allogeneic transplantation at a median time of 1.5 months following initial consultation (range 1-7) P = 0.001 (Figure 2) .
A second important question when considering alternative donor allogeneic transplantation is the incidence and severity of GVHD. Extensive T cell depletion using the One-Step Positive/Negative Selection System (Isolex 300i) in combination with pre-transplant administration of Thymoglobulin provided an efficient and reliable prophylaxis of severe acute GVHD. Anti-thymocyte globulin has been used for many years in allogeneic stem cell transplantation. The type of ATG, the administration of ATG pre-or post transplant, and the dose of ATG appear to be important factors on the overall clinical impact of ATG in allogeneic transplantation. It is difficult to compare results of clinical transplant studies that used different ATG products and administration schedules. Thymoglobulin is purified gamma immunoglobulin from rabbits that have been immunized with fresh human thymocytes. Thymoglobulin with its single IgG isotype, appears to be more potent in T cell depletion in humans than horse ATG. Thymoglobulin contains polyclonal anti-lymphocyte antibodies targeted to a broad range of human blood cell antigens. The combination of potent anti-T cell effect and prolonged half-life of Thymoglobulin post transplant provides a sustained in vivo T cell depletion effect following haplo-identical PBSC transplant.
Relapse and post transplant infections were major clinical problems in this small series of PMRD transplant patients. Both problems are likely related to the profound T cell depletion used in this study and the significant delay in T cell reconstitution post transplant (Figure 3) . Two refractory leukemia patients developed early invasive pulmonary aspergillosis (6 and 13 days post-transplant), which was probably related to prior colonization/infection associated with prolonged neutropenia. Two patients died of penicillin-resistant Streptococcus mitis sepsis (6 and 8 days post transplant) in the setting of severe mucositis. More aggressive prophylactic antimicrobial therapy may reduce these complications, and in our more recent experience the incidence of fatal bacteremia has markedly been reduced. Data from the larger series reported from Perugia and our own series support the graft-versus-leukemia (GVL) effect in PMRD transplantation in spite of the severe T cell depletion employed. 19 The three long-term survivors in our series of 19 patients were at very high risk for relapse based upon their prior history or unfavorable cytogenetics (one CML CP2, one ALL CR2 (Ph+), one AML CR1 Bone Marrow Transplantation (monosomy 7)). While T cell reconstitution did not occur until 3 months post transplant, NK cell recovery was rapid and robust. Recently an NK cell-mediated GVL mechanism following PMRD transplants was published. 20 NK cells which lack specific killing inhibitor receptor (KIR) epitopes in the GVL direction may provide a unique GVL effect preventing relapse in AML patients. 20 Based upon these promising preliminary data we have adopted KIR typing as part of our donor selection criteria. Currently, we attempt to identify donor-recipient pairs that are mismatched at class I loci that predict enhanced donor-versus-host NK cellmediated cytotoxicity (KIR mismatch). A formal prospective examination of the role of KIR mismatch in relapsefree survival following haplo-identical transplantation will be the subject of a future multi-center study. No conclusion on potential NK cell alloreactivity can be drawn in our small series of patients.
In conclusion, our pilot study results showed rapid and stable donor origin hematopoietic engraftment without severe non-hematopoietic system toxicity. All of our patients had high-risk disease and they were not eligible for HLAmatched related or unrelated donor transplant. Mismatched family donor transplant provided a readily available potentially curative therapy for many patients who would otherwise not be candidates for allogeneic transplantation.
Prospective, multi-institutional, randomized trials are needed to evaluate the role of NK cell mediated alloreactivity, as well as testing new approaches to improve cellular immune reconstitution following haplo-identical transplant.
